Related Experiment Video

Updated: Sep 11, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Experience with insulin analogues in children

Thomas Danne1, Dorothee Deiss, Werner Hopfenmüller

  • 1Diabetes-Zentrum für Kinder und Jugendliche, Kinderkrankenhaus auf der Bult, Hannover, Germany. danne@hka.de

Hormone Research
|April 30, 2002
PubMed

Insights

Rapid-acting and long-acting insulin analogues show potential benefits for children with diabetes, but long-term effects on glycemic control require further study. Continuous glucose monitoring aids in tailoring insulin analogue treatments for optimal results.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Limited data exists on rapid- and long-acting insulin analogues in pediatric populations.
  • Hypoglycemia reduction is noted with insulin analogues, but long-term glycemic control remains debated.
  • Continuous glucose monitoring (CGM) presents a novel approach for personalized insulin analogue therapy.

Purpose of the Study:

  • To evaluate the efficacy and safety of insulin analogues in pediatric patients with diabetes.
  • To assess the role of continuous glucose monitoring in optimizing insulin analogue treatment regimens.
  • To compare postprandial rapid-acting insulin analogue administration with preprandial regular insulin.

Main Methods:

  • A study involving 29 adolescents with diabetes.
  • Utilized continuous glucose monitoring systems to tailor insulin analogue therapy.
  • Compared postprandial rapid-acting analogue administration against preprandial regular insulin.

Main Results:

  • Confirmed non-inferiority of postprandial rapid-acting analogue versus preprandial regular insulin.
  • Observed significant mealtime variations, indicating increased analogue needs at breakfast and dinner.
  • Highlighted the potential benefits of insulin analogues in addressing common pediatric diabetes challenges.

Conclusions:

  • Insulin analogues may offer advantages in pediatric diabetes management.
  • Continuous glucose monitoring facilitates personalized treatment adjustments.
  • Long-term clinical observation is crucial to determine the individual value of insulin analogues in children.

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...